Latest Treatment News in Neuroendocrine Tumours
Afinitor is currently paid for by provincial drug plans for patients with well-or moderately differentiated neuroendocrine tumours of pancreatic origin (pNET), in patients with unresectable, locally advanced or metastatic disease. [...]
CCO to provide Ga-Octreotate to Ontario patients free of charge in Sherbrooke A message from Helena Senta: “At this time, CCO is proceeding with PET scan approval for the [...]
On October 2, 2016, CNETS Canada held a Toronto Patient Education Day entitled PRRT Clinical Trial Update – PMH Site, with presentations by Dr. Rebecca Wong and Dr. Shereen Ezzat. [...]
Clinical benefit demonstrated with everolimus and pasireotide LAR alone or in combination in the first randomised, prospective study entirely dedicated to advanced lung and thymic carcinoids. In patients with advanced [...]
The Pan-Canadian Oncology Drug Review (pCODR) will be considering an application for the drug Everolimus (Afinitor) indicated for Gastrointestinal and Lung Neuroendocrine (NET) Tumours. Everolimus is a cancer medicine that [...]
We are pleased to announce that this week, we are officially launching our 177Lu-octreotate PRRT clinical trial at CHU de Québec, which is called: Personalized Peptide Receptor Radionuclide Therapy of [...]